Wakamoto Pharmaceutical Co (TSE:4512) Total Liabilities : 円3,310 Mil (As of Sep. 2024)

View and export this data going back to 1949. Start your Free Trial

What is Wakamoto Pharmaceutical Co Total Liabilities?

Wakamoto Pharmaceutical Co's Total Liabilities for the quarter that ended in Sep. 2024 was 円3,310 Mil.

Wakamoto Pharmaceutical Co's quarterly Total Liabilities declined from Dec. 2023 (円3,553.45 Mil) to Mar. 2024 (円3,394.98 Mil) and declined from Mar. 2024 (円3,394.98 Mil) to Sep. 2024 (円3,310.23 Mil).

Wakamoto Pharmaceutical Co's annual Total Liabilities increased from Mar. 2022 (円3,472.63 Mil) to Mar. 2023 (円3,804.89 Mil) but then declined from Mar. 2023 (円3,804.89 Mil) to Mar. 2024 (円3,394.98 Mil).

Wakamoto Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Wakamoto Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wakamoto Pharmaceutical Co Total Liabilities Chart

Wakamoto Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

4,036.34

3,186.90

3,472.63

3,804.89

3,394.98

Wakamoto Pharmaceutical Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24
Total Liabilities	Get a 7-Day Free Trial															3,504.39	3,779.22	3,553.45	3,394.98	3,310.23

Wakamoto Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Wakamoto Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1808.142	+	(0	+	587.014
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	999.826	+	0)
	=	3,395

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	15421.054	-	12026.072
	=	3,395

Wakamoto Pharmaceutical Co's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1790.875	+	(0	+	530.037
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	989.318	+	0)
	=	3,310

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	15256.746	-	11946.516
	=	3,310

Wakamoto Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Wakamoto Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Wakamoto Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wakamoto Pharmaceutical Co Ltd (TSE:4512) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330

Website

http://www.wakamoto-pharm.co.jp

Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.

Wakamoto Pharmaceutical Co Headlines

No Headlines